Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

ASTRAZENECA (AZN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 05:35:21 pm
6130 GBp   +0.46%
12/08Moderna Declines in Market Debut -- WSJ
DJ
12/04Glaxo Makes Big Cancer-Drug Bet -- WSJ
DJ
12/03GlaxoSmithKline to Acquire Tesaro for $4.16 Billion -- Update
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca : Results From Imfinzi Head and Neck Cancer Trial Negative

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 02:31am EST

By Carlo Martuscelli

AstraZeneca PLC (AZN.LN) on Friday announced negative results from a phase 3 clinical trial of its cancer drug Imfinzi as a treatment for recurrent or metastatic head and neck squamous cell carcinoma.

The company said neither Imfinzi alone, nor Imfinzi plus add-on therapy tremelimumab, increased overall survival for treated patients when compared with standard-of-care chemotherapy, missing the primary objective in the Eagle trial. The patients enrolled in study had previously had their disease advance following platinum-based chemotherapy.

The Anglo-Swedish pharmaceutical said that while the results were disappointing, it remained committed to evaluating Imfinzi as a potential medicine for patients with head and neck cancer.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA 0.46% 6130 Delayed Quote.19.70%
ASTRAZENECA -0.45% 706.2 Delayed Quote.24.22%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTRAZENECA
12/14LONDON STOCK EXCHANGE : Poor China data caps turbulent week for FTSE 100 as inve..
RE
12/12Eli Lilly, AC Immune Ink Alzheimer's Collaboration -- Update
DJ
12/11Circassia Pharmaceuticals to Acquire Full Tudorza Commercial Rights in US
DJ
12/11ASTRAZENECA : U.K. pharmas shrug off Brexit vote delay
AQ
12/10EUROPE MARKETS: European Stocks End Sharply Lower As Data Add To Worries Abou..
DJ
12/10LONDON MARKETS: FTSE 100 Dragged Lower As U.K.'s May Delays Brexit Vote
DJ
12/10Imfinzi-tremelimumab combo fails Phase III for head and neck cancer
AQ
12/10ASTRAZENECA : and Cancer Research UK launch Functional Genomics Centre to accele..
PU
12/08Moderna Declines in Market Debut -- WSJ
DJ
12/07Moderna Declines in Public-Market Debut
DJ
More news
Financials ($)
Sales 2018 22 099 M
EBIT 2018 5 691 M
Net income 2018 2 361 M
Debt 2018 14 455 M
Yield 2018 3,51%
P/E ratio 2018 41,23
P/E ratio 2019 35,00
EV / Sales 2018 5,10x
EV / Sales 2019 4,81x
Capitalization 98 273 M
Chart ASTRAZENECA
Duration : Period :
AstraZeneca Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 80,5 $
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA19.70%98 273
JOHNSON & JOHNSON-4.81%356 703
PFIZER23.05%254 040
NOVARTIS5.61%223 295
ROCHE HOLDING LTD.1.38%216 307
MERCK AND COMPANY35.92%198 877